Advertisement

Long term oncologic outcome in patients with bladder cancer after radical cystectomy: Impact of carcinoma in situ in the era of neoadjuvant chemotherapy

  • Erfan Amini
  • Nariman Ahmadi
  • Thomas G. Clifford
  • Cory M. Hugen
  • Soroush T. Bazargani
  • Jie Cai
  • Gus Miranda
  • Andy E. Sherrod
  • Siamak Daneshmand
  • Hooman DjaladatEmail author
Urology - Original Paper

Abstract

Purpose

To assess the impact of carcinoma in situ (CIS) on oncologic outcomes in patients who underwent radical cystectomy, with a focus on those who received neoadjuvant chemotherapy (NAC) including patients with down-staging to ≤ pT1cancer after chemotherapy.

Materials and methods

All patients who underwent radical cystectomy for urothelial cancer with curative intent from 1985 to 2011 were included. The impact of CIS on recurrence free and overall survival (OS) was assessed in the whole cohort and a subgroup who received NAC as well as those with response to chemotherapy and down-staging to ≤ pT1.

Results

A total of 2518 patients with a median follow-up period of 9 years were included. Among all, 1397 (55.5%) had concomitant CIS on final pathology. CIS was associated with high risk pathologic features including high-grade disease, multifocality, and nodal involvement as well as worse recurrence free survival (RFS) with no impact on OS. We did not find a significant association between CIS and oncologic outcomes in a subset of patients who received NAC including those with down-staging to ≤ pT1 disease. In multivariate analysis, CIS had no association with either recurrence free or OS.

Conclusions

Concomitant CIS in radical cystectomy specimens is associated with decreased RFS; however, in multivariate analysis, it was not an independent predicting factor of oncologic outcomes. Moreover, the impact of CIS on oncologic outcomes in a subset of patients who received NAC was insignificant.

Keywords

Carcinoma in situ Cystectomy Neoadjuvant therapy Survival Urinary bladder neoplasms 

Notes

Compliance with ethical standards

Conflict of interest

All authors declare no conflicts of interests.

Ethical approval

All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the Helsinki declaration.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7CrossRefGoogle Scholar
  2. 2.
    Kulkarni GS, Hermanns T, Wei Y et al (2017) Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. J Clin Oncol 35:2299CrossRefGoogle Scholar
  3. 3.
    Williams SB, Shan Y, Jazzar U et al (2018) Comparing survival outcomes and costs associated with radical cystectomy and trimodal therapy for older adults with muscle-invasive bladder cancer. JAMA Surg 153:881CrossRefGoogle Scholar
  4. 4.
    Reardon ZD, Patel SG, Zaid HB et al (2015) Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. Eur Urol 67:165CrossRefGoogle Scholar
  5. 5.
    Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666CrossRefGoogle Scholar
  6. 6.
    Smits G, Schaafsma E, Kiemeney L et al (1998) Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression. Urology 52:1009CrossRefGoogle Scholar
  7. 7.
    Shariat SF, Karakiewicz PI, Palapattu GS et al (2006) Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 176:2414CrossRefGoogle Scholar
  8. 8.
    Parker WP, Ho PL, Melquist JJ et al (2015) The effect of concomitant carcinoma in situ on neoadjuvant chemotherapy for urothelial cell carcinoma of the bladder: inferior pathological outcomes but no effect on survival. J Urol 193:1494CrossRefGoogle Scholar
  9. 9.
    Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859CrossRefGoogle Scholar
  10. 10.
    Dyrskjot L, Kruhoffer M, Thykjaer T et al (2004) Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 64:4040CrossRefGoogle Scholar
  11. 11.
    Vicente J, Laguna MP, Duarte D et al (1991) Carcinoma in situ as a prognostic factor for G3pT1 bladder tumours. Br J Urol 68:380CrossRefGoogle Scholar
  12. 12.
    Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466CrossRefGoogle Scholar
  13. 13.
    Nuhn P, Bastian PJ, Novara G et al (2011) Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery. Urol Int 87:42CrossRefGoogle Scholar
  14. 14.
    Shariat SF, Palapattu GS, Karakiewicz PI et al (2007) Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol 51:152CrossRefGoogle Scholar
  15. 15.
    Yafi FA, Aprikian AG, Chin JL et al (2014) Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer. World J Urol 32:1295CrossRefGoogle Scholar
  16. 16.
    Masood S, Sriprasad S, Palmer JH et al (2004) T1G3 bladder cancer–indications for early cystectomy. Int Urol Nephrol 36:41CrossRefGoogle Scholar
  17. 17.
    International Collaboration of T, Medical Research Council Advanced Bladder Cancer Working P, European Organisation for R, et al (2011) International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29:2171CrossRefGoogle Scholar
  18. 18.
    Meeks JJ, Bellmunt J, Bochner BH et al (2012) A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 62:523CrossRefGoogle Scholar
  19. 19.
    Petrelli F, Coinu A, Cabiddu M et al (2014) Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. Eur Urol 65:350CrossRefGoogle Scholar
  20. 20.
    Zargar H, Zargar-Shoshtari K, Lotan Y et al (2015) Final Pathologic stage after neoadjuvant chemotherapy and radical cystectomy for bladder cancer: does pT0 predict better survival than pTa/Tis/T1? J Urol 195(4):886–893Google Scholar
  21. 21.
    Cowan NG, Chen Y, Downs TM et al (2014) Neoadjuvant chemotherapy use in bladder cancer: a survey of current practice and opinions. Adv Urol  https://doi.org/10.1155/2014/746298 Google Scholar
  22. 22.
    Bostrom PJ, van Rhijn BWG, Fleshner N et al (2010) Staging and staging errors in bladder cancer. Eur Urol Suppl 9:2–9Google Scholar
  23. 23.
    Saadat SH, Al-Tawil MO (2011) Risk factors for disconcordance between pre and post radical cystectomy stages. Urol J 8:291Google Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  • Erfan Amini
    • 1
    • 2
  • Nariman Ahmadi
    • 1
  • Thomas G. Clifford
    • 1
  • Cory M. Hugen
    • 1
  • Soroush T. Bazargani
    • 1
  • Jie Cai
    • 1
  • Gus Miranda
    • 1
  • Andy E. Sherrod
    • 3
  • Siamak Daneshmand
    • 1
  • Hooman Djaladat
    • 1
    • 4
    Email author
  1. 1.Institute of Urology, Norris Comprehensive Cancer CenterUniversity of Southern CaliforniaLos AngelesUSA
  2. 2.Department of Urology, Uro-Oncology Research CenterTehran University of Medical SciencesTehranIran
  3. 3.Department of Pathology, Norris Comprehensive Cancer Center, Keck School of MedicineUniversity of Southern CaliforniaLos AngelesUSA
  4. 4.Institute of Urology, USC/Norris Comprehensive Cancer CenterUniversity of Southern CaliforniaLos AngelesUSA

Personalised recommendations